Protein (2)Antibody (2)
En ligne (4)
Human respiratory syncytial virus A (strain A2) (1)Human respiratory syncytial virus B (strain B1) (1)Mouse (2)
His Tag (2)- (2)
Unconjugated (4)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT RSV-M662 | HEK293 | Monoclonal Anti-RSV-post-F0 specific Antibody, Human IgG1 (1A2D9D8) (MALS verified) | |||||
HOT RSF-V52H6 | Human respiratory syncytial virus A (strain A2) | HEK293 | HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified) | ||||
HOT RSF-V52H9 | Human respiratory syncytial virus B (strain B1) | HEK293 | HRSV (B) Post-fusion glycoprotein F0, His Tag (MALS verified) | ||||
RSV-Y180 | Hybridoma | Monoclonal Anti-RSV-post-F0 specific Antibody, Mouse IgG1 (1A2D9D8) (MALS verified) |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| RGN-259 | Fx peptide; TB4 16-38; RGN-457; Thymosin beta 4-16-38; Thymosin B4; RGN-352; RGN-259; RGN-137; Tβ4; TB4; GBT-201; GBT-101; Thymosin beta4 | Phase 3 Clinical | National Institutes Of Health | Keratitis; Myocardial Ischemia; ST Elevation Myocardial Infarction; Myocardial Infarction; Graft vs Host Disease; Sjogren's Syndrome; Dry Eye Syndromes; Epidermolysis Bullosa; Pressure Ulcer; Epidermolysis Bullosa, Junctional; Varicose Ulcer; Diabetes Mellitus; Epidermolysis Bullosa Dystrophica | Details |
| Fasinumab | SAR-164877; MT-5547; R-475; REGN-475 | Phase 3 Clinical | Abdominal Pain; Sciatica; Osteoarthritis, Knee; Back Pain; Osteoarthritis; Low Back Pain; Osteoarthritis, Hip | Details | |
| MEDI-7352 | MEDI-7352 | Phase 2 Clinical | Medimmune | Chronic Pain; Diabetic Neuropathies; Osteoarthritis, Knee | Details |
| N-Hexacosanol | tCFA15; TAC-302 | Phase 2 Clinical | Meiji Seika Pharma Co Ltd | Urinary Bladder, Underactive; Urinary Bladder, Overactive | Details |
| Antibodies to humanized nerve growth factor(Shenyang Sunshine Pharmaceutical) | Phase 2 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Bone metastases; Cancer Pain | Details | |
| EP-9001A | EP-9001A | Phase 2 Clinical | Chengdu Youluo Biotechnology Co Ltd | Bone metastases; Cancer Pain; Pain | Details |
| DS-002 | DS-002 | Phase 2 Clinical | Dartsbio Pharmaceuticals Ltd | Pain; Cancer Pain | Details |
| Atinumab | NG-101; ATI-355 | Phase 2 Clinical | Novartis Pharma Ag | Spinal Cord Injuries; Gastroparesis; Diabetic Gastroparesis | Details |
| SSS-40 | SSS-40; SSS-40-anti-NGF Ab; SSS40 anti-NGF Ab | Phase 1 Clinical | 3sbio Inc | Cancer Pain; Bone Neoplasms; Osteoarthritis | Details |
| Luvagrobart | AK-115 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Pain; Cancer Pain | Details |
| TNM-009 | TNM-009; TNM009 | Phase 1 Clinical | Zhuhai Trinomab Pharmaceutical Co Ltd | Cancer Pain; Pain | Details |
| SMR-7694 | SMR-7694; SMR7694 | Phase 1 Clinical | Sinobioway Biomedicine Co Ltd | Osteoarthritis | Details |
| Neuroregenerative agents (iNtRON Biotechnology) | Clinical | Intron Biotechnology | Nervous System Diseases | Details |




